This heterogeneity underscores the complex biology of neuroblastoma and the differing responses to treatment, which are likely influenced by factors such as tumor genetics (e.g., MYCN amplification), prior treatment exposure, and patient age [27]. This evidence concerns the gene MYCN and neuroblastoma.